Argent Capital Management LLC Boosts Stock Position in Halozyme Therapeutics, Inc. $HALO

Argent Capital Management LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.0% in the second quarter, HoldingsChannel.com reports. The firm owned 12,714 shares of the biopharmaceutical company’s stock after purchasing an additional 609 shares during the period. Argent Capital Management LLC’s holdings in Halozyme Therapeutics were worth $661,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Alliancebernstein L.P. raised its stake in Halozyme Therapeutics by 4.8% in the first quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company’s stock worth $205,156,000 after buying an additional 146,677 shares in the last quarter. Congress Asset Management Co. raised its stake in Halozyme Therapeutics by 8.8% in the first quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company’s stock worth $136,088,000 after buying an additional 172,971 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Halozyme Therapeutics by 4.9% in the first quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company’s stock worth $129,478,000 after buying an additional 95,600 shares in the last quarter. TD Asset Management Inc raised its stake in Halozyme Therapeutics by 5.8% in the first quarter. TD Asset Management Inc now owns 1,451,842 shares of the biopharmaceutical company’s stock worth $92,642,000 after buying an additional 79,708 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. raised its stake in Halozyme Therapeutics by 27.3% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company’s stock worth $72,107,000 after buying an additional 242,167 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Trading Up 0.6%

Shares of Halozyme Therapeutics stock opened at $78.28 on Tuesday. The company’s fifty day simple moving average is $67.54 and its 200-day simple moving average is $61.22. The stock has a market capitalization of $9.16 billion, a PE ratio of 17.91, a P/E/G ratio of 0.43 and a beta of 1.19. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $79.31. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.31. The business had revenue of $325.72 million for the quarter, compared to analysts’ expectations of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company’s revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HALO. JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th. Wall Street Zen downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 5th. Zacks Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 2nd. Morgan Stanley raised their target price on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an “overweight” rating in a research note on Monday, August 18th. Finally, The Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a research note on Thursday, July 10th. They set a “neutral” rating and a $55.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $68.22.

Insider Activity

In other news, CFO Nicole Labrosse sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the sale, the chief financial officer directly owned 24,306 shares in the company, valued at $1,840,207.26. This trade represents a 45.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bernadette Connaughton sold 4,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the sale, the director owned 46,952 shares in the company, valued at $3,459,423.36. The trade was a 7.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 84,000 shares of company stock worth $5,696,520 in the last three months. Company insiders own 2.90% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.